A Study Of Treatment Discontinuation For Chronic Hepatitis B Patients

Grant number: 1066536 | Funding period: 2014 - 2018

Completed

Abstract

Guidelines currently recommend lifelong treatment for patients with chronic hepatitis B, with associated cost and risks of drug resistance and side effects. It has recently been suggested that up to 50% of patients may safely and successfully stop drug after long-term treatment. Our project will identify which patients can safely stop treatment, by performing detailed studies of the human immune system and the hepatitis B virus. This will be an important advance for patient care.